< Inthera is tackling “undruggable” targets with innovative chemistry for the design of small molecule inhibitors of intracellular protein-protein interactions. The most advanced of these first-in-class therapeutics, an oral modulator of dysregulated transcription, is currently entering the preclinical stage. >

Ulrich Kessler, PhD
CEO

Inthera Bioscience AG / Einsiedlerstrasse 34 / CH-8820 Waedenswil

Ulrich Kessler, PhD
CEO


Inthera Bioscience AG
Einsiedlerstrasse 34
CH-8820 Waedenswil